BioSpace News Archive

Eclipse Bioinnovations, a leading RNA genomics company developing and commercializing novel, data-driven technologies that interrogate RNA, announced the launch of its eSHAPE™ suite of technologies that enable exploration of RNA secondary structure from RNA samples.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+).

Arima Genomics, Inc. and Pierian, now a part of Velsera, the precision engine company which enables the democratization of omic data across clinical and research applications, today announced co-marketing and licensing agreements that will provide enhanced gene fusion detecting capabilities to clinical labs.

Avania, a leading, global medical technology contract research organization (CRO), today announced its acquisition of MAXIS, a prominent medical technology development service provider with expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management.

Genetic Technologies Limited today announced the closing of its previously announced registered direct offering with several institutional investors for the purchase and sale of 3,846,155 American Depositary Shares (“ADSs”), each representing six hundred (600) ordinary shares of the Company, at a purchase price of $1.30 per ADS.

JR Automation is proud to release FlexChassis™, an exciting modular automation platform that expands the company’s portfolio of turnkey solutions for manufacturers.

Hardy Diagnostics proudly announces the launch of CompactDry TCR, a ready-to-use dehydrated culture medium plate for the detection and enumeration of microorganisms that provides total aerobic plate counts in as little as 24 hours.

Allosteric Bioscience, Inc., announced today that Dr. Susan Michaelis has joined its Scientific Advisory Board (SAB).

Optimi Health Corp. is pleased to announce the submission of its clinical trial application (CTA) for a Phase I combinatorial study that will document the safety of Optimi’s natural psilocybin standardized extract and proprietary 3,4-methylenedioxy-methamphetamine (MDMA) drug candidate in healthy therapist subjects.

A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from studies conducted with Humanetics Corporation’s (Humanetics) new radioprotective drug, BIO 300, finding that BIO 300 is uniquely effective at protecting against radiation-induced lung injury.